Yoh Takekuma
Overview
Explore the profile of Yoh Takekuma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saito Y, Takekuma Y, Komatsu Y, Sugawara M
Support Care Cancer
. 2025 Mar;
33(4):263.
PMID: 40064694
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in patients treated with gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer, negatively impacting their quality of life....
2.
Taniguchi O, Saito Y, Yamaguchi Y, Sakai M, Ikezawa Y, Sakakibara-Konishi J, et al.
Case Rep Oncol
. 2025 Feb;
18(1):151-158.
PMID: 39980523
Introduction: We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan. Case Presentation: A...
3.
Yagisawa K, Kubota A, Imai S, Nashimoto S, Sato Y, Kashiwagi H, et al.
Biol Pharm Bull
. 2025 Jan;
48(1):33-38.
PMID: 39864854
Using a large health insurance database in Japan, we examined the real-world usage of budesonide enteric-coated capsules (BUD) in treating Crohn's disease. We analyzed data from the Japan Medical Data...
4.
Mori A, Kato I, Narumi K, Takekuma Y, Ishikawa S, Kashiwagi H, et al.
Biol Pharm Bull
. 2025 Jan;
48(1):17-22.
PMID: 39842806
We have previously used the Roter Interaction Analysis System (RIAS) to analyze differences between online and face-to-face medication counseling. In our previous research, students have commented that the built-in camera...
5.
Yamagami A, Narumi K, Saito Y, Furugen A, Imai S, Okamoto K, et al.
Oral Dis
. 2025 Jan;
PMID: 39791448
Objectives: To externally validate a clinical prediction model for surgical site infection (SSI) after lower third molar (L3M) surgery and evaluate its clinical usefulness. Methods: We conducted a retrospective cohort...
6.
Yamaguchi A, Hirabayashi S, Niki K, Kagami K, Terashita Y, Cho Y, et al.
Int J Hematol
. 2024 Dec;
121(2):244-251.
PMID: 39625679
Therapeutic drug monitoring (TDM) of busulfan (BU) is useful for achieving the target area under the curve (AUC) because its effective plasma-concentration range is narrow. This preliminary observational study evaluated...
7.
Saito Y, Taniguchi O, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, et al.
Support Care Cancer
. 2024 Nov;
32(12):829.
PMID: 39601964
Background: Carboplatin (CBDCA) plus pemetrexed (PEM) is a commonly-used thoracic cancer treatment. As both CBDCA and PEM are excreted via the kidneys, renal impairment (RI) can lead to severe neutropenia,...
8.
Nishimura A, Furugen A, Kobayashi M, Takekuma Y, Yakuwa N, Goto M, et al.
J Pharm Health Care Sci
. 2024 Nov;
10(1):70.
PMID: 39516928
Background: Famotidine, a histamine2-receptor antagonist (H2Ras), is widely used to treat and prevent gastrointestinal symptoms during pregnancy. Although several studies have reported the use of H2Ras during pregnancy, limited data...
9.
Mikami R, Imai S, Hayakawa M, Kashiwagi H, Sato Y, Nashimoto S, et al.
J Pharm Health Care Sci
. 2024 Nov;
10(1):69.
PMID: 39506834
Background: Augmented renal clearance (ARC) decreases the therapeutic concentration of drugs excreted by the kidneys in critically ill patients. Several ARC prediction models have been developed and validated; however, their...
10.
Saito Y, Takekuma Y, Komatsu Y, Sugawara M
Sci Rep
. 2024 Nov;
14(1):26990.
PMID: 39506021
Trifluridine/tipiracil (FTD/TPI) with or without bevacizumab is an effective treatment for metastatic colorectal cancer (mCRC). As this agent is mainly excreted via the kidney, we aimed to evaluate the impact...